Autolus Therapeutics (AUTL) Misses Q2 EPS by 4c

Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.26), $0.04 worse than the analyst estimate of ($0.22).

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.

You May Also Be Interested In

• Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
• Vertex (VERX) Tops Q2 EPS by 1c; Offers Guidance
• Advanced Energy Industries (AEIS) Tops Q2 EPS by 54c; offers guidance